Preclinical studies hint at a common neuropathological mechanism of PAH action being the binding of these compounds to the aryl-hydrocarbon receptor (AhR), a cytosolic transcription factor that initiates a complex pathway leading to alteration of gene regulation. The gene discussed is AHR; the disease is pulmonary arterial hypertension.